Team Led by Klauber-Demore uses Antibody to Inhibit Tumor Growth

April 22, 2013 -- A monoclonal antibody targeting a protein known as SFPR2 has been shown by researchers at the University of North Carolina to inhibit tumor growth in pre-clinical models of breast cancer and angiosarcoma.

Team Led by Klauber-Demore uses Antibody to Inhibit Tumor Growth click to enlarge Angiosarcoma cells treated with a monoclonal antibody targeting SFRP2 (right) show a significant reduction compared to an untreated control (left). UNC/Demore Lab

A team lead by Nancy Klauber-DeMore uses a monoclonal antibody to effectively reduce the rate of tumor growth. To read the article click here.